Debt | 7. Debt The following table sets forth the items which comprise debt for the Company: March 31, December 31, 2018 2017 Revolving line of credit $ 1,596,072 $ 1,879,047 Subordinated promissory notes $ — $ 350,000 Total term notes payable, net of issuance costs $ 4,258,104 $ 4,346,194 Less current portion, net 393,481 367,779 Term notes payable, non-current, net 3,864,623 3,978,415 Total short and long term debt, net $ 5,854,176 $ 6,575,241 Bank Debt On December 29, 2017, the Company entered into a three -year $9,500,000 asset based credit and security agreement (“credit agreement”), with a Massachusetts trust company, replacing the credit facility with the Company’s previous lender. The credit agreement also provided funds with which to discharge the subordinated promissory notes. The credit agreement includes a revolving line of credit of up to $5.0 million (“Revolver”), a machinery and equipment term loan of $2.5 million (“Equipment Loan”) and a real estate term loan of $2.0 million (“Real Estate Loan” and together with the “Equipment Loan” the “Term Loans”). The Revolver is subject to certain borrowing base limitations. Amounts available to borrow under the revolver are $1,222,135 at March 31, 2018. Term Loans The Equipment Loan requires monthly principal payments of approximately $29,762 , payable on the first day of each month commencing February 1, 2018. The Equipment Loan is based upon an 84 month amortization with a balloon payment of approximately $1,458,333 due and payable in full upon maturity on December 29, 2020 . The Real Estate Loan requires monthly principal payments of approximately $8,333 , payable on the first day of each month commencing February 1, 2018. The Real Estate Loan is based upon a 240 month amortization with a balloon payment of approximately $1,708,333 due and payable in full upon maturity on December 29, 2020 . Interest on the Term Loans shall be at such Wall Street Journal prime rate plus 0.75% ( 5.164% at March 31, 2018). In lieu of having interest charged at the Prime Rate, the Company shall have a LIBOR Option, as described above, to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.5% for the following month. All interest will be calculated based upon a year of 360 days for actual days elapsed. Interest is payable monthly in arrears. Upon the occurrence and during the continuation of an Event of Default, all interest will be increased by 2% above the per annum rate otherwise applicable thereto. The Term Loans carry a prepayment penalty with respect to the prepayment of any portion of either Term Loan equal to 3% , 2% , and 1% of the amount prepaid in the first, second, and third years, respectively, of the asset based credit and security agreement . This credit agreement contains covenants related to various matters including certain financial covenants, prohibitions on further borrowings and security interests, merger or consolidation, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, and payment of dividends. The lender has a security interest in all assets and a mortgage encumbering certain real property. Oher Debt Subordinated promissory notes In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes and issued warrants to purchase 100,000 shares of common stock. Three related parties participated in the private offering as follows: REF Securities, LLP, and with Mr. Rodd E. Friedman, a director of the Company, a beneficial owner of approximately 12% of the Company’s common stock, invested $100,000 in the offering; the Chambers Medical Foundation (the “Foundation”), beneficial owner of approximately 11% of the Company’s common stock, invested $100,000 in the offering; and Mr. E.P. Marinos, then a director of the Company, invested $50,000 in the offering. The Company’s Chairman of the Board is a co-trustee of the Foundation but has held no dispositive powers since his appointment as such. On December 29, 2017, as part of entering into the credit agreement, the Company obtained funds to discharge the remaining $450,000 of subordinated debt. On December 29, 2017, the Company paid one of the subordinated notes in the principal amount of $100,000 . The remaining five notes, totaling an aggregate principal amount $350,000 , were discharged on January 2, 2018, including the subordinated notes held by the three related parties mentioned above. The Company carried $350,000 as restricted cash at December 31, 2017 for this purpose. In connection with the private offering of subordinated promissory notes, the Company issued 100,000 warrants to purchase the Company's common stock, including 20,000 warrants to REF Securities, LLP, 20,000 warrants to the Foundation and 10,000 warrants to Mr. Marinos. The warrants were initially exercisable through December 2016 at an exercise price of $3.51 per share. In October 2016, in connection with the extension of the maturity dates of the subordinated promissory notes, the expiration date of the remaining unexercised 70,000 warrants was extended to December 31, 2018. The discharge of the subordinated promissory notes as described above did not affect the maturity date of the warrants. The exercise price remained unchanged at $3.51 per share. The 70,000 warrants remain unexercised at March 31, 2018. |